New SGLT2 inhibitor ertugliflozin: safe and effective in the management of type 2 diabetes
Type 2 diabetes mellitus (T2DM) is closely associated with the risk of developing cardiovascular complications. A new approach to treatment of T2DM, based on the inhibition of the sodium-glucose cotransporter type 2 (SGLT2) ensures reliable insulin-independent glycemic control with quick overcome of...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Remedium Group LLC
2020-05-01
|
| Series: | Медицинский совет |
| Subjects: | |
| Online Access: | https://www.med-sovet.pro/jour/article/view/5653 |
| _version_ | 1797841603896803328 |
|---|---|
| author | V. V. Salukho T. A. Ilyinskay |
| author_facet | V. V. Salukho T. A. Ilyinskay |
| author_sort | V. V. Salukho |
| collection | DOAJ |
| description | Type 2 diabetes mellitus (T2DM) is closely associated with the risk of developing cardiovascular complications. A new approach to treatment of T2DM, based on the inhibition of the sodium-glucose cotransporter type 2 (SGLT2) ensures reliable insulin-independent glycemic control with quick overcome of glucotoxicity, reduction of insulin resistance, and positive effects on body mass, blood pressure and other rates. Besides, pronounces clinical efficacy of SGLT2 inhibitor is marked by its use safety and minimized frequency of adverse events. Along with this, the results of carried-out, randomized clinical studies of cardiovascular safety of different SGLT2 inhibitors showed, that apart from bearing on the risk factors, the inhibition of sodium-glucose cotransporter type 2 leads to cardioand renoprotective effects. In addition, their influence on cardiovascular and renal outcomes is the stronger the more different the pre-existing status of cardiovascular diseases of the patient is, the condition of his renal function and the severity of albuminuria. This article summarizes the main results of carried-out randomized clinical studies of SGLT2 inhibitors, which demonstrate their cardiovascular advantages and compile encouraging results of multicentered studies VERTIS, examining different aspects of the use of the ertugliflazine SGLT2 inhibitor in patients with type 2 diabetes. There is data provided demonstrating a powerful glucoselowering, body-mass lowering and hypotensive impacts of ertugliflazine comparable to the same performance of the best representatives of the class. This article describes an evidence base of the use of the drug in monotherapy and its ability to be combined with other oral hypoglycemic agentsand highlightes a high level of safety of the use of ertugliflazine correspondinding to minimized frequency of adverse outcomes of SGLT2 inhibition and so the potential of SGLT2 inhibitors as a new promising class for the treatment of patients with type 2 diabetes and established cardiovascular disease is revealed. |
| first_indexed | 2024-04-09T16:33:58Z |
| format | Article |
| id | doaj.art-01573fa923f0487ca9f950c28247db71 |
| institution | Directory Open Access Journal |
| issn | 2079-701X 2658-5790 |
| language | Russian |
| last_indexed | 2024-04-09T16:33:58Z |
| publishDate | 2020-05-01 |
| publisher | Remedium Group LLC |
| record_format | Article |
| series | Медицинский совет |
| spelling | doaj.art-01573fa923f0487ca9f950c28247db712023-04-23T06:56:57ZrusRemedium Group LLCМедицинский совет2079-701X2658-57902020-05-0107324110.21518/2079-701X-2020-7-32-415144New SGLT2 inhibitor ertugliflozin: safe and effective in the management of type 2 diabetesV. V. Salukho0T. A. Ilyinskay1S.M. Kirov Military Medical AcademyS.M. Kirov Military Medical AcademyType 2 diabetes mellitus (T2DM) is closely associated with the risk of developing cardiovascular complications. A new approach to treatment of T2DM, based on the inhibition of the sodium-glucose cotransporter type 2 (SGLT2) ensures reliable insulin-independent glycemic control with quick overcome of glucotoxicity, reduction of insulin resistance, and positive effects on body mass, blood pressure and other rates. Besides, pronounces clinical efficacy of SGLT2 inhibitor is marked by its use safety and minimized frequency of adverse events. Along with this, the results of carried-out, randomized clinical studies of cardiovascular safety of different SGLT2 inhibitors showed, that apart from bearing on the risk factors, the inhibition of sodium-glucose cotransporter type 2 leads to cardioand renoprotective effects. In addition, their influence on cardiovascular and renal outcomes is the stronger the more different the pre-existing status of cardiovascular diseases of the patient is, the condition of his renal function and the severity of albuminuria. This article summarizes the main results of carried-out randomized clinical studies of SGLT2 inhibitors, which demonstrate their cardiovascular advantages and compile encouraging results of multicentered studies VERTIS, examining different aspects of the use of the ertugliflazine SGLT2 inhibitor in patients with type 2 diabetes. There is data provided demonstrating a powerful glucoselowering, body-mass lowering and hypotensive impacts of ertugliflazine comparable to the same performance of the best representatives of the class. This article describes an evidence base of the use of the drug in monotherapy and its ability to be combined with other oral hypoglycemic agentsand highlightes a high level of safety of the use of ertugliflazine correspondinding to minimized frequency of adverse outcomes of SGLT2 inhibition and so the potential of SGLT2 inhibitors as a new promising class for the treatment of patients with type 2 diabetes and established cardiovascular disease is revealed.https://www.med-sovet.pro/jour/article/view/5653type 2 diabetes mellitushyperglycemiachronic heart failurerisk factorssglt2 inhibitorertugliflozin |
| spellingShingle | V. V. Salukho T. A. Ilyinskay New SGLT2 inhibitor ertugliflozin: safe and effective in the management of type 2 diabetes Медицинский совет type 2 diabetes mellitus hyperglycemia chronic heart failure risk factors sglt2 inhibitor ertugliflozin |
| title | New SGLT2 inhibitor ertugliflozin: safe and effective in the management of type 2 diabetes |
| title_full | New SGLT2 inhibitor ertugliflozin: safe and effective in the management of type 2 diabetes |
| title_fullStr | New SGLT2 inhibitor ertugliflozin: safe and effective in the management of type 2 diabetes |
| title_full_unstemmed | New SGLT2 inhibitor ertugliflozin: safe and effective in the management of type 2 diabetes |
| title_short | New SGLT2 inhibitor ertugliflozin: safe and effective in the management of type 2 diabetes |
| title_sort | new sglt2 inhibitor ertugliflozin safe and effective in the management of type 2 diabetes |
| topic | type 2 diabetes mellitus hyperglycemia chronic heart failure risk factors sglt2 inhibitor ertugliflozin |
| url | https://www.med-sovet.pro/jour/article/view/5653 |
| work_keys_str_mv | AT vvsalukho newsglt2inhibitorertugliflozinsafeandeffectiveinthemanagementoftype2diabetes AT tailyinskay newsglt2inhibitorertugliflozinsafeandeffectiveinthemanagementoftype2diabetes |